For oral semaglutide, skip the missed dose and continue the next morning never double up
Wegovy pills (oral, 25 mg daily) chronic weight management, approved December 2025
Tirzepatide is a dual agonist that engages both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors
Multiple freeze-thaw cycles, which can happen inadvertently in a poorly calibrated refrigerator, will progressively destroy the remaining active peptide until the preparation is essentially inert
Our study will have a major impact on clinical guidelines for the management of chronic kidney disease and cardiovascular disease in people with and without diabetes. More work is now needed to implement the results of this study into clinical practice and improve access to GLP-1 receptor agonists to people who will benefit from them, he added
| Curex Blue Shield of CA limits new Wegovy weight-loss starts to BMI 40+ since Jan 2025